The 17th R&D Meeting...Innovations in the IVD business Enhancing the Operational Value of Blood Coagulation Analyzers Applying Astrego’s Microchannel Technology Using AI Technology

March 6, 2020

Sysmex Corporation

The 17th R&D Meeting

■ The information contained in these materials is based on current judgements and assumptions of the Sysmex Group in light

of the information currently available to it. Uncertainties inherent in such judgments and assumptions, the future course of our

business operations and changes in operating environments in Japan and overseas may cause plans to change.

■ These materials contain information about products, service and support (including those under development). This

information is not intended for advertising or promotional purposes.

Index

1 Opening Presentation Hisashi IetsuguChairman and CEO

2 Technology Strategy Overview(1) Progress on Initiatives for the Realization of

Personalized Medicine

(2) Compact Immunoassay System and Initiatives

Targeting Coronavirus

3 Initiatives for the Realization of Personalized Medicine I

Kaoru AsanoMember of the Managing Board and

Senior Executive OfficerSenior Managing Director

COO LS Business Unit and CTO

Mamoru KubotaSenior Executive Officer

(1) Overview of Cancer Gene Testing in the LS Business

(2) Liquid Biopsy Gene Testing Initiatives

(3) Cancer Genomic Medicine Initiatives

Tomokazu YoshidaExecutive Officer

Executive Vice President of Central Research Laboratories(1) Initiatives Targeting Alzheimer’s Disease

(2) Applying Circulating Tumor Cells Measurement Technology

5 Technology Innovation in theIVD Business

Hiroshi KandaMember of the Managing Board and

Senior Executive OfficerManaging Director(1) Enhancing the Operational Value of Blood Coagulation Analyzers

(2) Applying Astrego’s Microchannel Technology

(3) Using AI Technology for Blood Imaging Analysis

Initiatives for the Realization of Personalized Medicine Ⅱ

4

(Appendix) Glossary

Hisashi Ietsugu, Chairman and CEO

1 Opening Presentation

Unique & Advanced Healthcare Testing Company

Long-Term Vision

・ An attractive company providing value and instilling confidence

・ A solution provider contributing to the advancement of primary care diagnostics

・ One Sysmex carrying out high-speed management

Positioning

Sysmex’s Long-Term Management Goals

Long-Term Management

Goals(2025)

Mid-Term Management Plan

(to March 2022)

・ A leading company in personalized diagnostics for optimizing medical treatment

・ Creating innovative diagnostic value as a global top-five company in IVD

4

Recognition of the External Environment

5

Changes in the

external

environment

Growth

fields

Developing countries

Emerging countries

Developed countries

Rising populations

Economic growth

Building of medical infrastructure

Epidemics of infectious disease

Falling birthrates and aging populations

Rapidly rising medical expenses

Technological innovation

Hematology, urinalysis, clinical chemistry, others

Hemostasis, immunochemistry, FCM, others

Business related to personalized medicine

Demographic changes and accelerating technological

innovation are giving rise to a host of medical issues and

growing markets to address these issues.

6

Acquire technologies

through open

innovation and M&A

Engineering technologies

•Mechanics

•Fluids

•Optics

•Electronics

Reagent development

technologies

•Chemical

reagents

•Bio reagents

•Data management

•Services and

support

ICT technologies

Sysmex’s Technologies

Improvements in testing productivity

Development of reagents with high clinical value

Network solutions providing more efficient healthcare and

enhanced services and support

OutputsTo medical institutions

in 190 countries

Environmentally considerate product development (energy conservation, other aspects)

OutcomesFor 7.0 billion

patients and people

undergoing

screening around

the world

Sysmex’s Technologies and Value Creation

Helping to realize a fulfilling and healthy society

through unique technologies

+

Contribution to the creation of new diagnostic and treatment

methods

Contribution to

extending

healthy lifespans

Help in curtailing

healthcare

expenses

Expanding Our R&D Bases

Techno Center (From 1991) Technopark (From 2008)

• Reinforce product development in the IVD business

• Start moving into the life science field

• Accelerate initiatives targeting personalized medicine

• Acquire diverse and specialized human resources and technologies

Reagents in environmentally conscious paper packs

Unique reagents for HISCL Series automated immunoassay systems

RD-200 gene amplification detector

XN Series multiparameter automated hematology analyzer

Technopark East Site (From 2019)

• Procure materials for, develop and produce bio-diagnostic reagents, and strengthen the logistics function

CN Series fully automated blood coagulation analyzer

OncoGuide NCC OncoPanel System

OncoBEAM RAS CRC kit

New network solution

Central Research Laboratories (2000)

Main building 40th anniversary of establishment 50th anniversary of establishment

7

IVD Business Life Science Business

Strengthening our R&D and technology bases, creating new products and services

Enhancing our R&D functions overseas, acquiring technologies through M&A, promoting open innovation

Automatic measurement

of red blood cells infected

by malaria parasites

Sysmex’s Growth Strategy

In addition to sustainable growth in the

IVD business, increase the rate of growth

by transforming our portfolio

Create new added value in the IVD domain

IVD business

Initiatives targeting personalized

medicine

⚫ Cancer genomic medicine

• BEAMing

• NCC OncoPanel

⚫ Liquid biopsy

• Alzheimer’s disease

• CTC

Innovations in the IVD business

⚫ Enhancing the Operational

Value of Blood Coagulation

Analyzers

⚫ Applying Astrego’s

Microchannel Technology

⚫ Using AI Technology for

Blood Imaging Analysis

Today’s agenda

Other new businesses

Life science business

Develop products and

services that contribute to

personalized medicine

Create new value that addresses

medical issues

8

Kaoru AsanoMember of the Managing Board and Senior Executive Officer,

Senior Managing Director,

COO LS Business Unit and CTO

2 Technology Strategy Overview

(1) Progress on Initiatives for the Realization of Personalized

Medicine

(2) Compact Immunoassay System and Initiatives Targeting

Coronavirus

10

Medicine

In vitro

diagnostics

(IVD)

Internal medical

treatment

(therapeutic drugs)Surgical

treatment

Health managementExpansion of technology

platforms centered on

liquid biopsy

Utilization of

technology assets

toward new medical

technologies

Expansion of product

portfolio for emerging

markets

Utilization of

testing data

Regenerative medicine / cell therapy / gene

therapy

Personalized

medicine

Preventive and preemptive medicine

Emerging markets

Technology Strategy Overview: The Healthcare Market

Minimally invasive sample collection of disease-

derived components in the blood (bodily fluid)Biopsy

Liquid biopsy

Invasive sample collection

of affected organ/tissue

Cells

Genes

Proteins

Technology Platform

Compared with conventional methods, liquid biopsy is in the spotlight

for its potential for imposing less of a burden on patients, increasing

opportunities for testing and helping to determine treatment methods

at an early stage.

Liquid Biopsy

Detection sensitivity: 100 to 1,000 times higher than conventional methods

11

12

Promote open innovation to develop applications with high clinical value and

place them on the technology platforms we have established

＋

(2) Applications

Universities, medical and

research institutions,

pharmaceutical manufacturers

and venture companies

Biomarkers

(1) Technology platforms

Open Innovation

13

Super-resolution

microscope

Clinical PCR

Plasma-Safe-SeqS

OSNATM

(RD)

FCM(XN, UF, LC)

HISCLTM

MI-FCM (CTC)

Clinical sequencing Clinical FCM

Ultrahigh-sensitivity

HISCL

HISCLTM

MI-FCM (Flow FISH)HISCLTM

(new markers)

OncoBEAM3.0

Cell measurement

platform

Genemeasurement

platform

Protein measurement

platform

Leverage

proprietary liquid

biopsy

technology to

drive

personalized

medicine

Capture

potential

markets

Expand

existing

market

Established Technology Platforms

We have completed the establishment of technology platforms and are

promoting the development applications with a view toward commercialization.

NCC Oncopanel

OncoBEAMTM RAS CRC

Alzheimer’s diseaseBreast cancer CTC

Panel for hereditary retinal degenerative diseases

Compact

immunoassay

CS, CN

14

Application Launch Plans

Clinical PCR

OncoBEAM3.0

Plasma-Safe-SeqS

~2019.3 ~2020.3 ~2021.3

Gen

es

Head and neck cancer panel

✔ ✔Breast cancer panel

RAS

✔EGFR

Immunoassay

systems

Super-resolution

microscope

Pro

tein

s

HDL function

measurement

✔

Alzheimer’s disease

Clinical sequencing

~2022.3

As indicated at the 16th R&D Meeting (Mar. 2019)

● RUO ● LDT ● IVD ● Other Note: Dotted lines indicate expectations

Flow FISH

CTC system

Cells

Hematopoietic malignancies

Breast cancer

Colon cancer panel

Transplant

testing

Immune checkpoint inhibitors(PD-1, PD-L1, CTLA4)

(Fiscal years to March 31)

15

Application Launch Plans (Update)

✔ ✔Breast cancer panel

RAS

✔EGFR

✔Alzheimer’s

disease

NCC

Oncopanel

✔IRD panelGIMSNCC

Oncopanel

✔

4 Gene panel(EGFR, ALK, ROS1, BRAF)

✔

Hematopoietic

malignanciesMultiple

myeloma

✔

Clinical PCR

OncoBEAM3.0

Plasma-Safe-SeqS

Gen

es

Immunoassay

systems

Compact

immunoassay

Pro

tein

s

Clinical sequencing

● RUO ● LDT ● IVD ● Other Note: Dotted lines indicate expectations

Flow FISH

CTC system

Cells

Head and neck cancer panel

Colon cancer panel

HDL function

measurement

Immune checkpoint inhibitors(PD-1, PD-L1, CTLA4)

~2019.3 ~2020.3 ~2021.3 ~2022.3

(Fiscal years to March 31)

HDL function

Gynecology

biomarker

Special

biomarkers

Transplant

testing

NCC Oncopanel

(next version)Developmental

delay

✔

Breast cancer Prostate cancer

2 Technology Strategy Overview

(1) Progress on Initiatives for the Realization of Personalized

Medicine

(2) Compact Immunoassay System and Initiatives Targeting

Coronavirus

17

Compact Immunoassay System

Jointly developed products with JVCKENWOOD Corporation

167mm 180mm

170mm

◼ High-sensitivity and rapid measurement

(within20 min.) provided by use of HISCL,

an automated immunoassay system,

reagents

◼ Compact unit allowing clinical installation

◼ Equipped with IoT function

◼ Simple to operate with smart phones or

other IT devices

Cartridge reagentsφ120mm t1.2mm

・All reagents pre-sealed

・No effluent

18

Operating Principle

Movie of Compact Immunoassay

19

Analytical Performance (TSH)

Measurement range

Lower limit Upper limit

μIU/ｍL 0.02 100~

Correlation

TSH: Thyroid stimulating hormone

Confirmed that its performance is almost the same as HISCL

Reagent cartridge

20

Start Consideration for Coronavirus Testing

Compact immunoassay system

HISCL

On-site testing (at clinics, etc.)

COVID-19 Ag Test

• Easy and rapid

• Lower price than PCR

For clinical laboratories and

testing institutionsCOVID-19 IgM Ab Test

COVID-19 IgG Ab Test

COVID-19 Ag Test

• Antigen / antibody test

(test the infection of patients who have

few virus in their specimen)

• Capable of processing a large

number of samples

Nasopharyngeal

specimen, etc.

Blood

Blood

Nasopharyngeal

specimen, etc.

Mamoru Kubota Senior Executive Officer

3Initiatives for the Realization of Personalized Medicine I




Overview of Cancer Gene Testing in the LS Business

(1) OSNA method (molecular detection of metastases in lymph nodes)Breast cancer, colorectal cancer, gastric cancer, lung cancer: Covered by insurance

(2) CurebestTM 95GC Breast / 55GC Colon (recurrence risk tests)Gene expression analysis in primary tumor for breast cancer and colorectal cancer: LDT/not covered by insurance

(3) OncoPrime, MSK-IMPACT (clinical sequence testing)Genome profiling of solid tumors: LDT/not covered by insurance

(4) OncoBEAM RAS CRC kit (liquid biopsy CDx)Determine suitability of anti-EGFR antibody drugs for colorectal cancer: Approved by

the Ministry of Health, Labor and Welfare, insurance coverage expected within 2020

(5) PSS/NGS (liquid biopsy gene panel test)Panel ctDNA profiling for breast cancer and colorectal cancer: LDT/not covered by insurance

(6) OncoGuideTM NCC Oncopanel system (cancer gene testing)

Solid tumor genome profiling: Covered by insurance

Surgical treatment, radiation therapy, pre- or post-operative drug therapy

Standard drug therapy(conventional anti-cancer drugs, hormone

therapy, molecularly targeted drugs, immune checkpoint inhibitor drugs)

Tu

mo

r lo

ad

Recurrence,

Metastasis

Resistance to

treatment

New drug therapy(treatment not covered by

insurance, administration of investigational new drugs)

22





24

Liquid Biopsy Gene Testing Initiatives

OncoBEAM RAS CRC kit

First companion diagnostic drug in the world to receive approval for ctDNA testing using the digital PCR method (July 19, 2019)

Detection of RAS (KRAS and NRAS) gene mutations in genomic DNA extracted from blood plasma <used to help determine suitability of Cetuximab (genetic recombinant) and Panitumumab (genetic

recombinant) for patients with colorectal cancer>

NRAS

• Codon 12

• Codon 13

• Codon 59

• Codon 61

• Codon 117

• Codon 146

KRAS

• Codon 12

• Codon 13

• Codon 59

• Codon 61

• Codon 117

• Codon 146

Configuration of a lab assay system

at the lab of SRL, Inc.

(introduction of the BEAMing 3.0 system)November 2019

Application for insurance coverage

July 2020

Expected start of insurance coverage

April 2020

Expected start of assessment

N=280 86.1％（89.2%**）

25

OncoBEAM RAS

blood plasma sample

RASKET

tissue sample

OncoBEAM RAS

tissue sample

NGS

blood plasma sample

N=294 93.9 ％*

N=100 96.0 ％*

British Journal of Cancer volume 120, pages982–986(2019)

Data 1

0 10 20 300

20

40

60

Discordance(N=11)Concordance(N=20)

Numberoflesionsinlung

Maxim

umSizeoflesioninlung(mm)

Discordance(N=11)Concordance(N=20)

As false negatives are possible, as much as

tissue tests were considered for patients with

lung metastasis only.

Analysis of cases of lung metastasis only

ESMO WCGC2018Oral presentation by Dr.

Yoshinori Kagawa, Department

of Gastroenterological Surgery,

Kansai Rosai Hospital

*Concordance rate

**Excluding cases of lung metastasis only

Number of lesions in lung

Base

line lo

ng

est d

iam

ete

r o

f lu

ng

lesio

n (

mm

)

Clinical Performance of OncoBEAM RAS CRC kit

Concordance (N=20)Discordance (N=11)

26

Clinical Utility of OncoBEAM RAS CRC kit

Retrospective study indicates a positive

prognosis (PFS and OS) for the patient

group with wild-type RAS genes in blood

plasma before administration of anti-EGFR

antibody drugs.

Sunakawa Y, et al. ESMO-GI 2019.

RAS gene

mutation test

Tumor tissue

Plasma

T0 T1 T2

Patients with advanced or recurrent

colorectal cancer

RAS gene

mutation test

Market

scale

Cancer Incidence in Japan*, Ministry of Health, Labour and Welfare (January 1 to

December 31, 2016) *Excluding intraepithelial cancer

“Cancer Statistics ’18,” Foundation for Promotion of Cancer Research (2018)

Number of patients in Japan with colorectal cancer: 158,127 pts/year

Number of RAS gene mutation tests: 25,546 test/year

Therapy selection

Wild-type

Mutant

Anti-EGFR antibody

therapy

Chemotherapy

Wild-type

Recurrent

Decision to repeat administration

of therapeutic drugs

Mutant

Overall survival rateProgression-free

survival rate





28

Cancer Genomic Medicine Initiatives

OncoGuide

NCC

Oncopanel

Increase target genes,

reduce costs• Addition of new clinical items

• Expansion of application before

using standard treatments

Analysis services

• GIMS (Genome Info. System)

• Quality assurance service

Genetic testing lab

total solution

(on-site business)

Expand portfolio

• Establishment and operational

support

• Analysis support

• Hereditary disease gene panel

• PSS/NGS liquid biopsy

29

OncoGuide NCC Oncopanel

Patie

nt e

xpla

natio

n

(exam

inatio

n)

Sam

ple

subm

issio

n

Conduct p

anel te

st

Expert P

ane

l

Report p

repara

tion

Patie

nt e

xpla

natio

n

(resu

lt)

Tre

atm

en

t

8,000 points 48,000 pointsC-CAT

June 1, 2019

Insurance coverage of cancer genome profiling using OncoGuid NCC Oncopanel (56,000 points)

Name: OncoGuid NCC Oncopanel System

OncoGuid NCC Oncopanel analysis program

OncoGuid NCC Oncopanel kit

Application: Obtaining a comprehensive genomic profile of tumor tissue in

patients with solid tumors

Target market: Japan

Target institutions: Medical institutions that have in place diagnostic systems

appropriate for cancer genome profiling

Medical equipment

production sales

authorization number:

23000BZX00398000

(approved as a combination medical device)

Target patients

Patients with solid tumors for which:

(1) No standard treatment exists

(2) Standard treatment has been

concluded

(or is expected to conclude)

Medical institution

Medical institution

Core hospital for cancer genomic medicine

30

Clinical Implementation of OncoGuide NCC Oncopanel

AGAAGCACCTGGAGAACTCATG.

....

TGCACACATTGACTTACCCACT.

....

AAGCAAAAATCCAGCCCATCAC.

....

CTTGGAAAAGGACTGCACTTGG.

....

CCTGGTGGTCTGGAAGATCTTC.

....

GCACCAGGAGGGACTTAGTTTA.

....

Open up the road to the use of therapeutic drugs not

covered by insurance and participation in clinical trials

Establish a flow of cooperation connecting affiliated institutions to conduct cancer gene testing

Core hospitals

(11)

Hub hospitals

(34)

Liaison hospitals

(161)

Note: As of January 1, 2020

Clinical testing company

Center for Cancer Genomics and Advanced Therapeutics

(C-CAT)

Expert Panel

C-CAT portal

https://www.jab.or.jp/

http://ord.yahoo.co.jp/o/image/RV=1/RE=1580186122/RH=b3JkLnlhaG9vLmNvLmpw/RB=/RU=aHR0cHM6Ly9hc3NldHMuY2xpcC1zdHVkaW8uY29tL2phLWpwL3NlYXJjaD90YWc9bHdv/RS=%5eADB8ojw_gHxdoawywbgXXL5QH93478-;_ylc=X3IDMgRmc3QDMD9yPTQxJmw9cmkEaWR4AzAEb2lkA0FOZDlHY1NsZkMxTmxEa21rRm1kWDVpNzlOSE5HUFhLVTJIYTcxRTQ4Vi1fTXNYR1NQcXJ1MDNIRjAtUmtRBHADNllHTDZZQ0I1THlhNTZTLjQ0T1Q0NE9yNDRLazQ0T3A0NEs1NDRPSQRwb3MDNDEEc2VjA3NodwRzbGsDcmk-

31

Contribution of ICT Technologies: OncoGuide Portal

Core hospitals,

hub hospitals

Expert Panel

OncoGuide Portal

ｖIPsec-VPN IPsec-VPN

Clinical

information

Clinical trial

information

System for sharing the

results of analysis

Sa

mp

le

info

rmatio

n

IPsec-VPN

All information can be confirmed

on C-CAT’s PCs

Creation of a system compliant with the security measures outlined in the Three Guidelines from Three Ministries

C-CAT Cancer Genome Testing Portal

C-CAT entry tool

Upload CDx analysis results

Test panel portal

Select the function you require.

Cancer Knowledge Database

(CKDB)

Cancer genome information

repository (genomic

information/clinical data)

C-CAT PC

Clinical Laboratory

Center

(Contractor)(genome analysis)

Ge

no

me

info

rmatio

n

An

aly

sis

in

form

atio

n

CKDB: Cancer Knowledge Data Base

32

Contribution Using ICT Technologies: GIMS

Arranging

schedules

Sharing

analysis

results

Sharing

patient

information

Expert Panel

Arranging schedules

Sharing

analysis results

Sharing

patient

information

Expert Panel

Genome Information System (GIMS)

➢ Expert Panel support systemConnects with OncoGuide Portal and provides support for advance preparations

• Simplifies the arrangement of schedules• Analysis and patient information can all be shared on this

system

Leveraging IT/AI and contributing to the standardization of cancer gene testing

Issues with Expert Panel• Needed to reduce the amount of time and effort needed to

arrange schedules among multiple institutions and participants

• Sharing information across multiple systems was complicated and complex

Expert Panel support system results

Before introduction

(Approx. 13 hours/week)

After introduction

(Approx. 4.5 hours/week)

Savings of

approx. 8.5

hours/weekA

dva

nce

pre

pa

ratio

ns

On

the

da

y

Expert Panel Support Provided by GIMS

33

Core hospitals, hub hospitals

Liaison hospitals

Core hospitals, hub hospitals

Prepare framework

Register information on

cases, test reports

(communicate with portal) Reserve expert panel

Approve reservation Panel fixed

Note: Images are all provisional

Trial underway at hospital affiliated

with Kyoto University

34

Comments about GIMS

GIMS has essentially eliminated the labor required to arrange schedules and confirm materials

for Expert Panel. Once schedules have been set, the system also automatically sends out

information to all the people involved at related institutions. The system has significantly

reduced the amount of work needed for arranging and holding Expert Panel.

The system is convenient, as it allows information to be checked easily and facilitates the

advance review of case data scheduled for review. The system provides solid peace of mind,

because information security is maintained whether viewing information from inside or outside

the hospital. We can browse information easily and quickly.

In the past, arranging for expert panels involved security issues and the efforts of two or

three people. Now, all the doctors (including those from other departments) have

accounts, so each one can manage the cases for which he is responsible.

In addition to reducing the burden on those of us who handle arrangements, I am

impressed that the system is covered under health insurance and can be managed

directly by doctors as part of their everyday operations.

Kumi Mukai, Specialist/Clinical Laboratory Technologist, Department of Therapeutic

Oncology, Graduate School of Medicine and Faculty of Medicine, Kyoto University

Masashi Kanai, Program-Specific Associate Professor, Department of Therapeutic

Oncology, Graduate School of Medicine and Faculty of Medicine, Kyoto University

Handling the data for cancer gene panel testing is very cumbersome. In the past, we had to

transfer data and reports manually, which presents the risk of mishandling. Now data can be

shared between OncoGuide Portal and the Expert Panel support system, allowing reports to be

checked, which significantly reduces the load on us.

Manabu Muto, M.D., Ph.D., Professor, Department of Therapeutic Oncology,

Graduate School of Medicine and Faculty of Medicine, Kyoto University

35

Development of Gene Panels for Hereditary Diseases

Aiming to create a gene panel for hereditary diseases (IVD/CDx)

Gene therapy:

Providing treatment to normalize the disease-causing genes resulting from gene

mutations (hereditary diseases)

Drug (company) Target disease Transgene Regions of approval:

Price

Glybera

(UniQure)

Lipoprotein lipase

deficiency

Lipoprotein lipase Europe: €820,000/pt

(sales discontinued)

Imlygic

(Amgen)

Malignant melanoma GM-CSF US: $65,000/pt

Europe: unknown

Strimvelis

(Orchard Therapeutics)

Adenosine deaminase

deficiency

Adenosine deaminase Europe: €594,000/pt

Zalmoxis

(MolMed)

Graft-versus-host

disease

HSV-TK Mut2 Europe: €149,000/time

Kymriah

(Novartis)

Acute lymphoblastic

leukemia

CD19-directed CAR

molecule

US: $475,000/time

Europe: €360,000/time

Japan: ¥33,490,000/time

Yescarta

(Kite Pharma)

Large B-cell

lymphoma

CD19-directed CAR

molecule

US: $373,000/time

Europe: unknown

Luxturna

(Spark Therapeutics)

Retinal dystrophy RPE65 US: $425,000/eye

Europe: €345,000/eye

Zolgensma

(AveXis)

Spinal muscular

atrophy

SMN1 US: $2,125,000/time

Japan: under review

Key gene therapy drugs that have recently been approved

Reference: Drug Delivery System 34-2, 2019. The price is according our research.

Cancer

Oncolytic

virus

Nucleic acid

medicine, adeno-

associated virus

(AAV)

CAR-TiPSCs,

hPSCs

Non-cells

Cells

Non-cancer

CAR-T: Chimeric Antigen Receptor-T cell、iPSCs: Artificial pluripotent stem cells、hPSCs: Human pluripotent stem cells

36

Development of Genomic Medicine for IRD

・ First institution in Japan specialized in ophthalmology

・ Actively conduct clinical researches and genetic counselings

・ Development of cancer genome profiling system

・ Experience in obtaining regulatory approval and insurance coverage 36

Comprehensive collaboration with the Kobe Eye Center Hospital

(March 5, 2020 release)

Inherited Retinal Disease(IRD)

➢ Hereditary diseases characterized by abnormalities of abnormalities

in the photoreceptor cells or epithelial cells that adhere to the retina.

➢ No fundamental treatment method exists, but gene therapy drugs

have been approved in the United States and Europe.

➢ At least 40 types of underlying genes exist. Not every genes are

clear yet.

Testing is needed to elucidate the underlying gene in order

to select the optimal method of treatment

IRD patients

NGS panel testing

Provide therapy optimized for

each underlying gene

・ Development of rare disease arrays・ Development of the NGS panel system

・ Gene analysis expertise・ Quality-assured consignment system

Aim to develop NGS panel testing (identification of the disease-causing genes) by

leveraging specialized skills at the Kobe Eye Center Hospital and the Sysmex

Group’s technologies and experience

IRD：Inherited Retinal Degeneration Dystrophy/Disease/Disorder

Tomokazu Yoshida

Executive Officer

Executive Vice President of Central Research Laboratories

4Initiatives for the Realization of Personalized Medicine II

(1) Initiatives Targeting Alzheimer’s Disease

(2) Applying Circulating Tumor Cells（CTC）Measurement

Technology

Liquid Biopsy (Alzheimer’s Disease)

38

Normal cognitive

function

Brain atrophy

(irreversible)

Deterioration of daily life functions, such as

memory impairment, leading to wandering about,

aggressive behavior and delusions

Early-stage detection and pre-emptive medical attention at the mild cognitive

impairment stage of Alzheimer’s disease are important.

Progression of Alzheimer’s disease

Aβ accumulation

Nerve damage due to tau

Brain atrophy

Memory impaired

Deterioration of

daily life functions

A quantitative, standardized system for

diagnosis is needed.

Mild cognitive impairment (MCI)

Dementia

Adapted from Lancet Neurol 2010; 9:119-128

Preclinical period

(normal cognitive function)

MCI Dementia

Normal

Abnormal

Cha

nge

of b

iom

ark

ers

No clear standards currently exist for diagnosing MCI.


Clinical trial

discontinued

Clinical trial

underway

Drugs targeting amyloid β are being developed to curtail disease-base deterioration

at an earlier stage.

39

Aducanumab

（Applying to FDA）Solanezumab

（Phase III）

Gantenerumab

（Phase III）

BAN2401

（Phase III）

Anavex 2-73

（Phase II/III）CAD106

（Phase II/III）

Crenezumab

（Phase II）Crenezumab

（Phase II）

Application

for approval

submitted

Normal Pre-symptomatic Alzheimer’s diseaseMCI

Alzheimers Dement (N Y). 2019; 5: 272–293.

Sources: Revised and adapted by Sysmex based on information from ClinicalTrials.gov, individual

companies’ press releases, and materials from a 2017 Eisai information meeting

40

Medical interview

(evaluation of cognitive function)

Diagnosis by exclusion

Symptomatic

treatment

Confirmed diagnosis

(post-mortem brain pathology)

Not objective or

quantitative

Cost-prohibitive, require

special facilities

Invasive, inadequacy of

testing items


The realization of blood tests for Alzheimer’s disease will help provide new

therapeutic opportunities.

Distinguishing Alzheimer’s

Disease

CDx

Blood tests

MCI early-

stage

diagnosis

(screening)

MCI

Dementia

Vascular, Lewy bodies Alzheimer’s disease Differentiation of

biomarkers an issue

Symptomatic

treatment

Imaging (MRI/CT, PET, etc.),

spinal fluid tests

×

×

×

×

・Simple (easy to

standardize)

・Quantitative

・Minimally invasive

・Multi-marker (therapeutic

target molecules, etc.)

41


Elements required for realization of blood tests

HISCL

Sysmex’s initiatives

1. Creation of a highly sensitive measurement system using HISCL

2. Verification of specificity of captured molecules (amyloid β)

3. Verification of concordance with PET test results (accumulation of

amyloid β in the brain)

4. Verification of results of markers related to Alzheimer’s disease other

than amyloid β

1. Highly sensitive measurement: Because target markers are present in the blood in

minute quantities

2. Highly specific measurement: To reduce the impact of blood-based similar molecules

and impurities

3. Scientific basis: Consistency of changes between marker behavior and brain imaging

4. Medical basis: Relationships between marker behavior and status of cognitive function

42


Measurement with HISCL enables highly sensitive and accurate detection of target

amyloid β.

Aβ1-40 Aβ1-42

Dynamic range [pg/mL] 8.6 – 975 0.7 – 895

Reproducibility CVs [%] 2 - 5 2 – 6

The accurate detection of amyloid β (Aβ40,

Aβ42) in the blood reportedly enables

prediction of the status of amyloid β

accumulation in the brain.Mass spectrometry

0

5

10

15

20

25

30

0 10 20 30

HIS

CL [

unit]

IP-MS [unit]

Mass

Sig

na

l str

en

gth

Aβ40, 42, other similar molecules

Conventional antibody combination

MassSig

na

l str

en

gth

Aβ42

New antibody combination

From a CTAD2019 poster

0

100

200

300

400

0 100 200 300 400

HIS

CL [

pg/m

L]

IP-MS [pg/mL]

Aβ1-40 in blood plasma

0

10

20

30

40

0 10 20 30 40

HIS

CLT

M s

eries [pg/m

L]

IP-MS [pg/mL]

Aβ1-42in blood plasma

r = 0.95 r = 0.92

Results of positive PET predictions in clinical subjects (n= approx. 200 cases) in amyloid PET diagnosis

CTAD2019 ポスターより


A high degree of concordance has been determine with amyloid PET

(status of amyloid β accumulation in the brain)

Background of subjects

(n=192)

Average age (standard

deviation)73.3 years (6.28)

Race: Caucasian / other 92.7% / 7.3%

Gender: Male / female 51.0% / 49.0%

APOE4: - / + 57.3% / 42.2%

MCI due to Alzheimer’s

disease84.9%

Early stage of mild

Alzheimer’s disease10.4%

Amyloid positivity in patients with clinical cognitive

dysfunction in clinical trials

Model1 = Aβ1-42/Aβ1-40, Model2 = Model1 + age + ApoE4

Model3 = Aβ1-42 + Aβ1-40, Model4 = Model3 + age + ApoE4

Model1 (AUC 0.74)

Model2 (AUC 0.82)

Model3 (AUC 0.74)

Model4 (AUC 0.81)

1-Specificity

Se

nsitiv

ity

0.00

0.00 1.000.750.500.25

1.00

0.75

0.50

0.25

Negative: Cognitive dysfunction without amyloid β accumulation in

the brain

Positive: MCI, mild AD with amyloid β accumulation in the brain

Sensitivity: 73%

Specificity: 71%

Note: When using cutoffs based on Youden Index in Model 1,43

◆Prediction performance of amyloid β accumulation

in the brain by IP-MS (Comparison with PET using

flutemetamol)

Sensitivity: 78.7% / specificity: 82.4%(From Nature. 2018 Feb 8; 554(7691): 249-254)

Stage of cognitive impairment

Bio

ma

rke

r p

rofile

A T N NormalMild cognitive

impairmentDementia

－－－ Normal Non AD

＋－－ AD cognitive

impairment

＋－＋ AD and Non AD

＋＋－Pre-symptomatic

ADProdromal AD AD

＋＋＋

44


Creation of an HISCL measurement system for parameters other than amyloid β

(total tau, phosphorylated tau)

Around the world, efforts are underway to classify the stages of

cognitive impairment by using ATN.(Research framework from the National Institute on Aging and the

Alzheimer’s Association)

Nerve cell death

Amyloid β

Tau

Adapted from Alzheimer’s Dementia. 2018 Apr; 14(4): 535-562

A: Amyloid β, T: Tau protein, N: Neurodegeneration / nerve damage

Blood: Subject measurement

results (n=9)

CN AD

t-ta

u [u

nit/m

l]

0

10

20

30

40

50

CN AD

p-t

au

[u

nit/m

l]

0

5

10

15

Total tau

Phosphorylated

tau

4Initiatives for the Realization of Personalized Medicine II

(1) Initiatives Targeting Alzheimer’s Disease

(2) Applying Circulating Tumor Cells（CTC）Measurement

Technology

Liquid Biopsy (CTCs)

46

Circulating tumor cells (CTCs), in combination with genetic information, have the

potential to facilitate optimized treatment.

Body Tissues or cellsCirculating tumor cells

(CTCs)

Circulating tumor DNA

(ctDNA)

Testing method MRI, CT, PETImmunostaining, FISH

NGS (cancer genome)CTC measurement system

High-sensitivity PCR

NGS

Invasiveness None High (surgery, biopsy) Low (only blood sampling via liquid biopsy)

Main

measurement

targets,

characteristics

Location, size Shape / gene / proteinDetailed analysis of protein

expression within a single cell

Simultaneous

measurement of multiple

genetic mutations

Originating tissue Can be identified Difficult to identify

Information

obtainedWhole body Localized Whole body

Impact on

treatment

Screening, severity,

monitoring of treatment

effects

Confirmed diagnosis,

severity, selection of

therapeutic drugs

Selection of drugs to target

expressed proteins

Selection of drugs to

gene mutations

Primary

tumor

Metastasized

tumor


We have finished building a system and plan to begin offering a lab assay service in

Japan and Singapore.

Biological and

medical verificationClinical verification

Lab Assay Services

for Research

Customer verification of clinical utility

Development of image analysis

methods leveraging data

Collaborative

research

MI-FCM CTC softwareReagent (CTC panel)Cell separation and concentration unit

・ Obtain pathological data on CTCs

・ Analyze single cells

・ Monitoring of treatment effects / consideration

of potential for treatment of metastatic tumors

Colo-rectal cancer

Lung

cancer

Prostate

cancer

Breast

cancer

Creation of clinical value with

a view to development for IVD

47

48


It is suggested that CTCs could be used to track changes in the expression status

of the molecules a drug targets.

Pathology results

Molecule X expression: Yes

Molecule Y expression: No

Treatment with drugs that

target X

0

100

200

Images of detected CTCs

Going forward, we plan to consider the clinical utility of

drug selection based on CTC information.

Potential for changing

the treatment by

changing the drug used

for treatment

Patient with untreated

stage 4 breast cancer

At initial diagnosis

During treatment

CT

Cs /5

mL

Bright field NuclearMolecule X Molecule Y

Bright field NuclearMolecule X Molecule Y

Hiroshi KandaMember of the Managing Board and Senior Executive Officer

Managing Director

5Technology Innovation in the IVD Business

(1) Enhancing the Operational Value of Blood Coagulation

Analyzers



50

CN Series (Launched in Japan in December 2018)

CN-6000/CN-3000 automated blood

coagulation analyzers

New CN Series meets the call

for further advances in

in vitro diagnostics

High-speed processing

Space-saving

Transport-compatible

Network support

Developed by installing new engineering technologies

51

Up 12.5%

Up 11.9%

Up 16.6%

Up 66.7%

(1)

(2)

(3)

(4)

Order pattern (ratio of sample numbers)

(1) Coagulation principle, single parameter PT

(2) Coagulation principle, multiple parameters PT(10)+APTT(10)+Fbg(10)

(3) Coagulation, turbidimetric immunoassay and

chromogenic substrate principles, multiple parametersPT(10)+APTT(8)+Fbg(5)+AT(2)+DD(3)+FDP(3)

(4) Coagulation, turbidimetric immunoassay and

chromogenic substrate principles, multiple parametersPT(10)+APTT(10)+Fbg(10)+AT(10)+DD(10)+FDP(10)

Achieves high-speed processing when measuring multiple parameters

CN-6000

CS-5100

CN Series (Launched in Japan in December 2018)

test/hour

52

Technologies Incorporated into the CN Series

Inside the pipette

Using high-pressure cleaning to shorten cleaning time

Report results

End point

Tra

nsm

itte

dlig

ht

inte

nsity

Detection time180 seconds (fixed)

8 second cycle

Analyze

End point

CS Series CN Series

Analyze Report results

Faster reporting due to an improved analysis algorithm

Generates turbulence for

better cleaning

Cleaning liquid forced out at

high speed

High-pressure

cleaning system

PipetteMetering syringe

ChamberHigh-pressurecleaning syringe

Electromechanical valve Backflow prevention valve

53

Life of maintenance-free light source: Five years or more

Multi-wavelength

detection method

Note: The halogen lamp on the CS

needed to be changed periodically,

having a life of 1,000 hours (less

than three months if operated 24

hours a day)

Shape of the needle tip

changed to an obtuse angle

Tripled the durability (to 120,000 piercings) and reduced

the dead volume when blood cells are layered

Enhanced durability and usability

CS Series CN Series

LED unit that takes over the

multi-wavelength function

Technologies Incorporated into the CN Series

Receiver

element

Halogen lamp

Optical fiber

Interference filter

54

Environmental Considerations in the CN Series (Compared with the CS-5100)

1. More compact and space saving

Volume reduced by approx. 50%

2. Power consumption

1,700VA→1,080VA

Reduced by approx. 36% due to improved Pelteir

element for cooling reagent

3. Transport efficiency

Weight: 420kg→370kg 12% CO2 reduction effect

Dimensional weight*: 516.6kg→376.5kg 27% reduction

*Dimensional weight (kg)

= Depth (cm) x width (cm) x height (cm) ÷ 6,000 (cm3/kg) container box size

Initiatives contribute to SDGs

50%

CS-5100 CN-6000/3000



Analyzers



Environment Surrounding Urinary Tract Infections

56

◼ Currently, infectious diseases still account for around 1/4 of deaths around the world. Malaria, tuberculosis, AIDS and

enteral infections are major problems in developing countries, and present urgent issues for multidisciplinary studies

(such as health and development studies) as well as infectious disease studies.

◼ In developed countries, in addition to emerging and re-emergent infectious diseases the spread of bacteria with

antimicrobial resistance is becoming a public health issue. Developments in advanced medical care and a growing

elderly population are leading to an increase in opportunistic infections among postoperative patients and patients in an

immunosuppressive state. Thus routine infectious disease are also becoming an issue.

◼ A number of people are affected by infectious respiratory-tract diseases, such as those of the upper respiratory tract, as

well as bladder infections and other urinary tract infections. This situation is emphasizing the importance of proper early-

stage diagnosis and treatment, including the proper use of antimicrobial drugs.

Source: Antimicrobial Resistance:

Tackling a crisis for health and wealth

of nations, the O’Neill Commission,

UK, December 2014

In 2015, the World Health Assembly endorsed the Global Action Plan on Antimicrobial

Resistance (AMR). Various countries are pursuing AMR countermeasures, and progress is

being reported by the WHO.

Cancer

Cholera

Diabetes

Traffic

accidents

Diarrheal

disease

Measles

Tetanus

(without any countermeasures)

◼ The process of obtaining test results needed for the appropriate diagnosis and treatment of infectious

disease involves cultivating bacteria and running identification and drug sensitivity tests. Currently,

results are reported in one–two days for hospitalized patients and more than four days for patients

handled by private practices. This situation does not contribute to the proper use of antimicrobial drugs

at the initial stage.

◼ When cultivated in Petri dishes, bacteria grow in all directions, forming colonies, and the process

generally takes 24 hours or more. Astrego’s technology involves growing bacterial in one direction

within microchannels. This approach allows small changes in growth to be observed, facilitating rapid,

30-minute tests. This is expected to contribute to appropriate diagnosis and treatment at the initial stage.

Drug sensitivity test

(18–24 hours)

Bacteria iden-

tification test

(several minutes)

Bacteria cultivation

(24–48 hours)

57

Technology for the Rapid Cultivation of Bacteria in Liquid Using Microchannels

Identification

testing

system

Drug

sensitivity

tester

Prototype machine Prototype cartridgeExploded view of microchannel

Bacteria

Bacteria

58

◼ Multiple channel conditions (different drugs and densities) can be set, allowing changes in growth rate

under different conditions to be compared to the reference channels. This approach allows

measurement for resistance to multiple antibacterial drugs.

◼ Different from gene testing, “living bacteria” are used to reveal drug resistance, providing more accurate

drug sensitivity test results. (Dead bacteria that do not express resistance are outside the scope of

measurement.)

Applying Microchannel Technology to Drug Sensitivity Tests

Reference channels (culture liquid only)

Measured channels (with antibacterial drugs)

Reference growth rate

Leveling off of growth: drug sensitivity exists



Analyzers



Using AI Technology in Hematology

SP-50 slide

preparation unit

Pos

Neg

Pos

DI-60 blood image

analyzer

60Tests are needed that can reduce the burden on laboratory technologists and are not skill-dependent.

Cell counting /

abnormality detection

Hematology testing flow Assumes university hospital-class facility using SP-50/DI-60

Laboratory

Diagnostics

and treatment

Approx. 2 min./patient

Microscopic

examination by

expert

technologists

(visual)

30%-50%

of all samples

10%-15%

of all samples

Blood test

Report

Summarize information

used for diagnosis and

consultation by doctors

Preparation of sample comments

Disease prediction

Assumptions for additional testing

Caresphere™

LWS laboratory information system

XN Series multiparameter

automated hematology analyzer

Neg


Pos

Neg

Neg

Pos

61

Potential to leverage AI

AI image

analysis

technology

Configuration of an automated system that performs

at least as well as expert laboratory technologists

Assumes university hospital-class facility using SP-50/DI-60

Laboratory

XN Series multiparameter

automated hematology analyzer

30%-50%

of all samples

SP-50 slide

preparation unit

DI-60 blood image

analyzer

10%-15%

of all samples

Cell counting /

abnormality detection

Several seconds/patient

Summarize information

used for diagnosis and

consultation by doctors

Preparation of sample comments

Disease prediction

Assumptions for additional testing

Blood test

Diagnostics

and treatment

Report

Caresphere™

LWS laboratory information system

62

Current initiatives and performance◼ Initiative

Extract and learn features of blood cell images using convolutional

neural networks

Cell images

digitalizedCell classification

Morphological

abnormalities

Training

dataset

Training

(1) Ability to differentiate images of blood cells

For all 19 cell types, differentiate to accuracy of 95% or higher

(2) Ability to detect cell abnormality

For 80% of abnormal cells, detect with an accuracy of 90% or higher

◼ Skills needed for AI image analysis and current performance


Department of Next-Generation

Hematology Laboratory Medicine

AUC 0.990

63

◼ Challenging to realize the technology to distinguish disease using AI image analysis

New initiatives

Paper published in Scientific Reports(*4), a series by Nature, a

UK-based journal (Published September 16, 2019)

In cases of hematopoietic stem cell abnormalities, ability to distinguish(*1) between MDS(*2)

and AA(*3) reaching 90%

(*1) Sensitivity, specificity

(*2) Myelodysplastic syndrome

(*3) Aplastic anemia

(*4) Scientific Reports : Impact factor 4.011

https://www.nature.com/articles/s41598-019-49942-z

Increase the performance of AI image analysis technology, combine with

existing hematology technology, and achieve new technological advancesTransform into clinical value that helps support diagnosis


AI image analysis technology

64

Future developments

Leading-edged technology to

elevate blood testing to the

next generation

Roll out a hematology digital platform as the

foundation of next-generation hematology testing technology


Global standard in

blood testing

Shaping the advancement of healthcare.

GlossaryAppendix

66

GlossarySlide No.

4 Primary care The initial care provided at clinics or other locations when a patient first falls ill.

4 IVDAcronym for “in vitro diagnostics.” Refers to in vitro diagnostic pharmaceuticals and products that

have received regulatory approval.

5 Personalized medicineThis type of medicine goes beyond the conventional practice of providing selected predetermined

or uniform treatment for a given disease. Instead, the selection of treatment is optimized for

individual patient characteristics, based on gene and other testing data.

7 RAS One of the gene that is known to cause cancer when it mutates.

8 BEAMingAn acronym for “Bead, Emulsion, Amplification, and Magnetics,” this gene analysis method

combines ultrahigh-sensitivity PCR and flow cytometry technologies for analysis of genetic

mutations.

8 Liquid biopsy

This is a general name for technology using blood or body fluid samples for diagnosis and the

prediction of treatment impacts rather than through the conventional practice of tissue biopsy, in

which diagnosis is performed on diseased tissue that has been collected. Liquid biopsy is less

invasive than tissue biopsy, but more highly sensitive detection technologies are required.

8 CTCAcronym for “circulating tumor cell.” CTCs refer to cancer cells that have broken away from

primary or metastatic cancer sites and are circulating in the blood.

8 Urinary tract infectionsThe urinary tract runs between the kidneys and the urethral opening. Inflammations due to the

incursion of bacteria into the urinary tract are known as urinary tract infections. Such infections

can lead to bladder inflammation and pyelonephritis (inflammation of the kidneys).

8 Drug susceptibility testA test to determine the efficacy of various antimicrobial drugs against pathogenic bacteria

detected in a sample.

10 Technology platformRefers to Sysmex’s three technologies - gene measurement, cell measurement and protein

measurement - and the measurement platforms that utilize them.

10 Regenerative medicineThis type of medicine seeks to repair, regenerate and restore function of tissues and organs that

have been lost, injured or lost function due to disease or accident by using cells and tissues

cultivated outside a patient’s body.

10Preventive/preemptive

medicine

Preventive medicine uses gene testing and other types of testing to diagnose and prognosticate

diseases that are likely to occur, and seeks to prevent their occurrence. Preemptive medicine

follows the onset of symptoms and seeks to prevent disease from becoming more serious.

12 Application Corresponds to a “test item” in Sysmex’s technology platforms.

67

GlossarySlide No.

13 Plasma-Safe-SeqS (PSS)Acronym for “Plasma-Safe-Sequencing.” This pretreatment technology is used to discern between

gene mutations and read errors by attaching tags to genes to be amplified.

13 PCRAcronym for “polymerase chain reaction.” A gene amplification technology for copying small

quantities of DNA to produce larger quantities.

13 FISHAn abbreviation of Fluorescence In Situ Hybridization. The term refers to a testing method that

uses fluorescent probe that binds only to specific genes to detect target genes within a

chromosome.

14 LDTAcronym for “laboratory developed test.” LDTs, often testing methods that have not received

regulatory approval, include highly sophisticated and complex gene testing that can only be

performed in specific clinical testing labs.

15 GIMS Acronym for "Genome Information Management System."

22 CDxShort for “companion diagnostics.” Clinical testing performed to predict the efficacy and side

effects of drugs before using them for treatment.

22 NGSAcronym for “next-generation sequencer.” May also refer to a next-generation sequencer, an

instrument for reading gene base sequences at high speed.

22 ctDNACancer-derived DNA circulating in the blood. A focus of growing attention as a non-invasive

cancer biomarker for testing using liquid biopsy.

29 Expert panel

A multidisciplinary investigative commission that meets to interpret gene panel testing results

medically. Convened at core hospitals for cancer genomic medicine, expert panels recommend

treatment methods optimized for individual patients on the basis of abnormal gene information.

Members of such panels include oncologists, genome researchers, counselors, etc.

29

Center for Cancer

Genomics and Advanced

Therapeutics (C-CAT)

A new cancer genomic medicine base established by the National Cancer Center. It was created

to collect and store nationwide information regarding genomic medicine and to create

mechanisms that enable the discovery of new medical treatments via the appropriate utilization

and application of this information.

31Three Guidelines from

Three Ministries

Three guidelines established by three Japanese ministries (the Ministry of Health, Labour and

Welfare; the Ministry of Economy, Trade and Industry; and the Ministry of Internal Affairs and

Communications) for the handling of electronic medical information.

35 iPSCs, hPSCsiPSCs are induced pluripotent stem cells. hPSCs are human pluripotent stem cells. hPSCs include

human-derived embryonic stem cells and iPSs.

38 Amyloid-β (Aβ)A key constituent of senile plaque, a pathological characteristic of the brain tissue of patients with

Alzheimer’s disease, composed of around 40 amino acids.

68

GlossarySlide No.

38 TauA microtubule-associated protein that exists in central neuronal cells. Along with senile plaque,

inordinately phosphorylated deposits of tau protein (neurofibrillary tangle) can be observed in the

brains of patients with Alzheimer’s disease.

38 MCI Acronym for "mild cognitive impairment."

40 Lewy body dementiaA cognitive disease caused by the expression of clusters of proteins (called Lewy bodies) in nerve

cells in the brain.

56 Antimicrobial resistanceThis phenomenon occurs when living organisms develop a resistance to a drug, whose efficacy is

reduced or nullified as a result. Bacteria that

have developed microbial resistance are known as antimicrobial-resistant bacteria.

57 Identification testA test to determine the name of bacteria that are the source of an infectious disease detected in a

sample.

60 Blood smear samplePrepared for microscopy of blood cell morphology by placing a drop of blood on a glass slide, and

then drying and staining it.

60 CaresphereTM

Caresphere utilizes IoT and the cloud to establish a platform for the real-time linking and analysis

of a variety of information managed using testing instruments and clinical laboratory information

systems. It is a new network solution that provides support for increasing the operational efficiency

of professionals involved in testing and healthcare, enhancing quality and raising patient

satisfaction.

63 Hematopoietic stem cells Cells that produce red blood cells, white blood cells and blood platelets in the bone marrow.

64 Digital platformNew platforms for business that are based on digital technology. Within the healthcare market,

this term refers to IoT platforms that support healthy lives and enable seamless care in terms of

prevention, diagnosis, treatment and home care.

The 17th R&D Meeting...Innovations in the IVD business Enhancing the Operational Value of Blood Coagulation Analyzers Applying Astrego’s Microchannel Technology Using AI Technology

Documents